PubRank

Jean-Marc Limacher

Author PubWeight™ 16.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011 3.53
2 Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011 2.57
3 A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011 1.85
4 A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008 1.47
5 A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2010 1.08
6 MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005 1.00
7 Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008 0.96
8 Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother 2015 0.83
9 The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer 2008 0.81
10 Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel 2007 0.80
11 A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 2003 0.80
12 Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. J Transl Med 2013 0.77
13 Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Curr Top Microbiol Immunol 2015 0.76
14 Cancer vaccines: challenges and outlook in the field. IDrugs 2007 0.75